POSTERS ASCO 2024

Cáncer ginecológico

Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.

Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.

Abstract: 5566 Poster Bd #: 437

Poster

Descargar

Autor
José Alejandro Pérez-Fidalgo, MD, PhD

Department of Medical Oncology, Hospital Clínico Universitario de Valencia

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON